Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer

D. Lorusso, G. Ferrandina, R. Lo Voi, A. Fagotti, Giovanni Scambia

Research output: Contribution to journalArticlepeer-review


Pegylated liposomal doxorubicin (PLD, Caelyx®) is an emerging option for patients with recurrent ovarian carcinoma. Several phase II studies showed promising activity of PLD in recurrent ovarian cancer patients with response rate ranging from 16 to 25%. A phase III randomized trial compared PLD 50 mg/m2 day 1 every 4 weeks with Topotecan 1.5 mg/m2 daily for 5 days q 21 in recurrent ovarian cancer patients. No differences in progression free survival and overall survival were documented between treatment arms in the general population but a survival advantage was reported for platinum-sensitive subset. Our experience with PLD in the treatment of ovarian cancer is reported in this review article. Pegylated liposomal doxorubicin is effective as a second line treatment in ovarian cancer patients; comparative data are needed to establish its role in first line therapy.

Original languageEnglish
Pages (from-to)98-103
Number of pages6
JournalJournal of Chemotherapy
Issue numberSUPPL. 4
Publication statusPublished - Nov 2004


  • Ovarian cancer
  • Pegylated Liposomal Doxorubin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)


Dive into the research topics of 'Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this